Britain and America have hammered out a significant commercial pact that will preserve zero duties on British drug products entering the American market.
The Terms of the Pact
As part of the deal, the UK has committed to increase spending on medicines through the NHS. This pledge secures that import taxes on these crucial exports will be held at zero for a timeframe of 36 months.
This deal comes after previous warnings to significantly raise duties on patented pharmaceutical products, with potential rates discussed up to one hundred percent.
"This arrangement between the Britain reinforces the international landscape for new treatments and establishes long-overdue equity to transatlantic medicine commerce," a release said.
Trade Significance
Medicines are one of the Britain's most significant export categories to the America, which is by far the biggest destination for leading UK drugmakers.
Statistics indicate that in the 12 months leading up to last September, the UK shipped pharmaceutical products valued at billions to the US. This figure accounted for 17.4% of total UK exports in that span.
"This agreement protects employment, stimulates capital expenditure and paves the way for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The pact includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise total public funding on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must refund to the NHS to control costs will be capped at 15%. In the past, refunds exceeded twenty percent.
Recent Tensions
This agreement comes amid a long-running row between the sector and the ministers over medicine costs and regulatory access.
These tensions were intensified by arguments that US customers were paying significantly more for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar investments have been announced toward American operations.
One official acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had declined as a share of its resources over the last ten years.
